Recursion Pharmaceuticals announced that it intends to offer and sell $200M of shares of its Class A common stock in an underwritten public offering. Goldman Sachs & Co. and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company is acting as book-running manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Recursion Pharmaceuticals Reveals Strategy at Download Day
- Recursion Pharmaceuticals gives guidance on seven clinical readouts
- Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
- Recursion Pharmaceuticals call volume above normal and directionally bullish
- Recursion to Participate in Upcoming Investor Conferences